ARTICLE | Clinical News
CVT-301: Phase I data
January 16, 2012 8:00 AM UTC
Top-line data from a dose-ranging Phase I trial in healthy volunteers showed that CVT-301 was safe and well tolerated. Additionally, CVT-301 was immediately absorbed with dose-proportional pharmacokin...